Ocular Therapeutix, Inc.
OCUL
Ocular Therapeutix, Inc., a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology. The company markets ReSure Sealant, an ophthalmic device to prevent wound leaks in corneal incisions following cataract surgery; and DEXTENZA, a dexamethasone ophthalmā¦ read more
Healthcare
Biotechnology
11 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$14.95
Price-2.97%
-$0.46
1Y
Price
Market Cap
$2.598b
Mid
Price/Earnings 3y Avg5y Avg
-
Premium
Premium
Financials Overview
Key metrics over the past few years-449.3%
EBITDA Margin-477.3%
Net Profit Margin-390.0%
Free Cash Flow MarginRevenue
$55.783m
-12.5%
1y CAGR+3.4%
3y CAGR+7.1%
5y CAGREarnings
-$249.673m
-29.0%
1y CAGR-60.8%
3y CAGR-291.6%
5y CAGREPS
-$1.44
-18.0%
1y CAGR-14.3%
3y CAGR-10.4%
5y CAGRBook Value
$258.229m
$410.882m
Assets$152.653m
Liabilities$77.008m
DebtDebt to Assets
18.7%
-0.3x
Debt to EBITDAFree Cash Flow
-$199.436m
-46.7%
1y CAGR-48.5%
3y CAGR-35.1%
5y CAGRFinancial Reports
Earnings and other important metrics. Amounts in USD.No items found.
Press Releases
Statements and updates from the company